Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 9/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 6/20 | 1.00 |
| ▸ | AHCY | P23526 | 7/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | PI4KA | P42356 | 3/20 | 0.64 |
| ▸ | PI4K2B | Q8TCG2 | 3/20 | 0.64 |
| ▸ | PI4K2A | Q9BTU6 | 3/20 | 0.64 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5810639 | 1.00 | ADORA2A (1.00) | ADORA2AADORA1AHCYALDH1A1PI4KA | |
| SCHEMBL904363 | 1.00 | ADORA2A (1.00) | ADORA2AADORA1AHCYALDH1A1PI4KA | |
| SCHEMBL29496348 | 1.00 | ADORA2A (1.00) | ADORA2AADORA1AHCYALDH1A1PI4KA | |
| SCHEMBL28855667 | 0.98 | ADORA2A (0.97) | ADORA2AADORA1AHCYALDH1A1PI4KA | |
| SCHEMBL16603993 | 0.87 | AHCY (0.85) | ADORA2AADORA1AHCYALDH1A1PI4KA | |
| SCHEMBL12620928 | 0.87 | ADORA2A (0.77) | ADORA2AADORA1AHCYALDH1A1PI4KA | |
| SCHEMBL6040056 | 0.86 | ADORA2A (0.75) | ADORA2AADORA1AHCYALDH1A1PI4KA | |
| SCHEMBL25861 | 0.86 | ADORA2A (0.75) | ADORA2AADORA1AHCYALDH1A1PI4KA | |
| SCHEMBL8815696 | 0.86 | ADORA2A (0.75) | ADORA2AADORA1AHCYALDH1A1PI4KA | |
| SCHEMBL16504492 | 0.85 | ADORA2A (0.74) | ADORA2AADORA1AHCYALDH1A1PI4KA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 385 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119708059-A | Post-production treatment method for tenofovir | 石家庄龙泽制药股份有限公司 | 2025-03-28 | — | — | CN | claimed |
| CN-115974921-B | Synthetic tenor Fuwei method | 浙江嘉化新材料有限公司 | 2025-03-14 | — | — | CN | claimed |
| CN-119431450-A | Preparation method of R-9- (2-methoxypropyl) adenine | 浙江工业大学 | 2025-02-14 | — | — | CN | claimed |
| CN-118994244-A | Synthetic preparation method of tenofovir | 石家庄龙泽制药股份有限公司 | 2024-11-22 | — | — | CN | claimed |
| CN-118005693-A | Preparation method of tenofovir alafenamide fumarate impurity | 安徽贝克制药股份有限公司 | 2024-05-10 | — | — | CN | claimed |
| CN-116731988-B | Total synthesis ketoreductase and preparation method using same | 重庆普佑生物医药有限公司 | 2024-04-05 | — | — | CN | claimed |
| CN-114409706-B | Preparation method of phenyl hydrogen phosphonate and intermediate thereof | 上海医药工业研究院 | 2023-11-28 | — | — | CN | claimed |
| CN-116854735-A | Synthesis method of tenofovir | 广西奕安泰药业有限公司 | 2023-10-10 | — | — | CN | claimed |
| CN-116731988-A | Total synthesis ketoreductase and preparation method using same | 重庆普佑生物医药有限公司 | 2023-09-12 | — | — | CN | claimed |
| CN-115974921-A | Method for synthesizing tenofovir | 浙江嘉化新材料有限公司 | 2023-04-18 | — | — | CN | claimed |
| CN-106046055-A | R-9-(2-phosphonomethoxy propyl)-adenine monohydrate crystals, preparation thereof and preparation of tenofovir disoproxil fumarate | 湖北丽益医药科技有限公司 | 2016-10-26 | — | — | CN | claimed |
| CN-105859781-A | Industrialization production technology for tenofovir disoproxil fumarate | 荆门市帅邦化学科技有限公司 | 2016-08-17 | — | — | CN | claimed |
| CN-104892613-B | A kind of new R-9-(2-hydroxypropyl) the purification process technique of adenine | 洛阳德胜生物科技股份有限公司 | 2016-06-29 | — | — | CN | claimed |
| WO-2015051874-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF TENOFOVIR DISOPROXIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | ZENTIVA, K.S. (CZ) | 2015-04-16 | — | — | WO | claimed |
| EP-2860185-A1 | An improved process for the preparation of Tenofovir disoproxil and pharmaceutically acceptable salts thereof | Zentiva, k.s. (CZ) | 2015-04-15 | — | — | EP | claimed |
| EP-2462935-B1 | Process for the preparation of tenofovir | LAURUS LABS PRIVATE LTD (IN) | 2015-01-21 | — | — | EP | claimed |
| US-8791259-B2 | Process for the preparation of Tenofovir | LAURUS LABS PRIVATE LIMITED (IN) | 2014-07-29 | — | — | US | claimed |
| US-20130165413-A1 | PROCESS FOR THE PREPARATION OF TENOFOVIR | APTUIT LAURUS PRIVATE LIMITED (IN) | 2013-06-27 | — | — | US | claimed |
| WO-2012081032-A1 | PROCESS FOR THE PREPARATION OF TENOFOVIR | APTUIT LAURUS PRIVATE LIMITED (IN) | 2012-06-21 | — | — | WO | claimed |
| EP-2462935-A1 | Process for the preparation of tenofovir | Laurus Labs Private Limited (IN) | 2012-06-13 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165413-A1 | PROCESS FOR THE PREPARATION OF TENOFOVIR | SAMHD1, TYMP, DCTPP1 | ADORA2A 2915/4885ADORA1 1096/4885AHCY 2497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.